ACL Laboratories
Now part of ADVOCATEHEALTH

Test Bulletin

June 2024

Advocate Health Implements New PO Box and Address Change for Remittance

Effective Monday, July 1, 2024, Advocate Health will make changes to ACL's remittance addresses and how we accept and process payments. While the change doesn't take place until Monday, July 1, 2024, we currently have established the P.O. Box and it is open and ready to receive payments.

Current Address	Address effective Monday, July 1, 2024
PO Box 343918 Milwaukee, WI 53234	PO Box 736190 Chicago, IL 60673-6190

For this change to be successful, we ask that you engage your internal representatives to determine how this remittance address change may impact your claims operations and make plans to implement any changes needed to ensure no payment processing delays occur with this change.

ACL Client Payment Address
Please send all payments and correspondence to the new PO Box listed above. If you have questions or concerns, please contact us via our Customer Service line at 1.800.877.7016, Option 1 or via email at ACLClientBilling@aah.org.

New Orderable Code for Cytomegalovirus by Qualitative PCR, Saliva

Effective Wednesday, June 19, 2024, Cytomegalovirus by Qualitative PCR, Saliva (Test Order Code LAB12376) will be available as an orderable test code with testing being performed at ARUP Laboratories. Providers will no longer have to utilize a Miscellaneous test code for ordering. Test information is below.

Test Information	Cytomegalovirus by Qualitative PCR, Saliva (Test Order Code LAB12376)
Specimen Type	Saliva
Collection Tube	ORACollect OC-100 kit
Temperature	Frozen
Stability	3 months
Methodology	Qualitative Polymerase Chain Reaction (PCR)
TAT	5 days
Performing Lab	ARUP

continued...

Created: 06/2024 | Created by: H. Barrie – ACL Business Development | Designed by: C. McDonough – Graphic Designer

CM-HB-2406a

ACL Implements New In-House Test UGT1A1 Genotyping

Test Order Code LAB12277

Effective Tuesday, June 18, 2024, ACL Laboratories will implement a new test UGT1A1 Genotyping (Test Order Code LAB12277).

Clinical Indication: This test is designed to detect pharmacogenomic variants in the UGT1A1 gene, which encodes the bilirubin UDP-glucuronosyltransferase (UGT) enzyme. Reduced UGT1A1 activity leads to the accumulation of unconjugated bilirubin. Drugs that inhibit UGT1A1 activity can also increase levels of plasma unconjugated bilirubin, increasing the risk of side effects such as jaundice, neutropenia, and diarrhea. Poor metabolizer of UGT1A1 substrates may be at risk for an adverse, toxic, or poor response to medications that inhibit or are inactivated by UGT1A1 and may benefit from alterations in dosing or drug selection.

Test Method: This test will be performed by ACL Laboratories using a laboratory developed test method based on PCR and fluorescent fragment size analysis.

Specimen Requirements: One pink (K2EDTA) 6 mL **OR** Two lavender (K2EDTA) 3 mL

Transport: 6 mL (minimum 1 mL) whole blood, refrigerated

Stability: Ambient: 72 hours; Refrigerated: 14 days; Frozen: Unacceptable

Unacceptable Conditions: Plasma, serum, FFPE tissue blocks/slides, decalcified or frozen tissue. Specimens collected in anticoagulants other than K2EDTA. Clotted or grossly hemolyzed specimens.

Performed: Weekdays

Performing Sites: IL Central Lab

Reporting Time: Final within 7 days

This new ACL assay has performance characteristics comparable to the current reference laboratory assay UGT1A1 Genotype and will detect the same variants (TA)nTAA promoter polymorphisms

*1=TA(6), *36=TA(5), *28=TA(7), and *37=TA(8).

If you have any questions, please contact:
ACL Molecular Pathology Laboratory at Rosemont (1.847.349.7182) or
ACL Client Services (1.800.877.7016)

Created: 06/2024 | Created by: H. Barrie – ACL Business Development | Designed by: C. McDonough – Graphic Designer CM-HB-2406a